PYXS – pyxis oncology, inc. (US:NASDAQ)

News

Pyxis Oncology Provides Corporate Update and Reports Financial Results for Third Quarter 2024
Pyxis Oncology to Host In-Person (NYC) and Virtual Investor Event on Wednesday, November 20, 2024, to Present Preliminary Data from the Phase 1 Dose Escalation Trial of PYX-201
Pyxis Oncology's Cancer Drug Platform Shows Potential, Analyst Sees Over 190% Upside [Yahoo! Finance]
Pyxis Oncology, Inc. (NASDAQ: PYXS) is now covered by analysts at Stephens. They set an "overweight" rating and a $13.00 price target on the stock.
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Pyxis Oncology, Inc. (NASDAQ:PYXS)
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com